{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:36:29Z","timestamp":1789497389464,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM), an incurable malignancy of plasma cells, is predominantly an age-related disease, with the majority of cases occurring in patients over the age of 60. Cellular senescence, a fundamental biological process underlying aging, has been increasingly recognized for its critical role in developing age-related malignancies. In this study, we aimed to investigate the prognostic significance of genes implicated in the molecular mechanisms of senescence within a large cohort of MM patients. Gene expression and clinical data from 1416 MM patients were obtained from four GEO datasets (GSE24080, GSE4204, GSE57317, and GSE9782) and integrated into a unified database. The raw data were processed using MAS5 normalization, scaling adjustments, and JetSet probe selection to ensure cross-platform comparability. A curated set of senescence-associated genes, the SenMayo gene signature, was employed for subsequent analyses. The final gene signature was computed as a weighted mean expression of 122 senescence-associated genes, with weights derived from univariate hazard ratios. Prognostic significance was evaluated using Cox regression, Kaplan\u2013Meier survival analysis, and multivariate models incorporating clinical parameters such as gender, isotype, and molecular subtypes. False discovery rate (FDR) correction was applied to ensure the statistical robustness of findings. The weighted SenMayo gene signature strongly correlated with overall survival in MM patients (HR\u2009=\u20090.6, 95% CI\u2009=\u20090.47\u20130.76, <jats:italic>p<\/jats:italic>\u2009=\u20091.7e-05). The 75th percent probability of survival was reached at 36.1\u00a0months in the low-expression patient group, compared to 57\u00a0months in the high-expression group. Independent validation in datasets with sufficient patient numbers confirmed the prognostic value of the SenMayo signature (GSE4204: HR\u2009=\u20090.58, 95% CI\u2009=\u20090.39\u20130.88, <jats:italic>p<\/jats:italic>\u2009=\u20090.0089; GSE24080: HR\u2009=\u20090.61, 95% CI\u2009=\u20090.45\u20130.83, <jats:italic>p<\/jats:italic>\u2009=\u20090.0012; GSE57317: HR\u2009=\u20090.25, 95% CI\u2009=\u20090.08\u20130.77, <jats:italic>p<\/jats:italic>\u2009=\u20090.0095). Multivariate analyses further established the SenMayo signature as an independent prognostic factor, even when accounting for established clinical parameters such as sex and isotype. These findings underscore the robustness and independence of the SenMayo gene signature as a predictor of overall survival in multiple myeloma. This signature provides clinically valuable insights into the role of cellular senescence in disease progression.<\/jats:p>","DOI":"10.1007\/s11357-025-01622-9","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:17:55Z","timestamp":1743200275000},"page":"5025-5037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic impact of a senescence gene signature in multiple myeloma"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-7518","authenticated-orcid":false,"given":"Andrea","family":"Lehoczki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otilia","family":"Menyhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajnalka","family":"Andrikovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Ungvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","volume":"45","author":"VS Urban","year":"2023","unstructured":"Urban VS, Cegledi A, Mikala G. Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. Geroscience. 2023;45:727\u201346. https:\/\/doi.org\/10.1007\/s11357-022-00698-x.","journal-title":"Geroscience"},{"key":"1622_CR2","doi-asserted-by":"publisher","first-page":"14564","DOI":"10.1038\/s41598-024-65590-4","volume":"14","author":"DT Zhu","year":"2024","unstructured":"Zhu DT, Park A, Lai A, Zhang L, Attar H, Rebbeck TR. Multiple myeloma incidence and mortality trends in the United States, 1999\u20132020. Sci Rep. 2024;14:14564. https:\/\/doi.org\/10.1038\/s41598-024-65590-4.","journal-title":"Sci Rep"},{"key":"1622_CR3","doi-asserted-by":"publisher","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, McShane C, Bray F, Znaor A. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst. 2024. https:\/\/doi.org\/10.1093\/jnci\/djae321.","DOI":"10.1093\/jnci\/djae321"},{"key":"1622_CR4","doi-asserted-by":"publisher","unstructured":"Fekete M, Major D, Feher A, Fazekas-Pongor V, Lehoczki A. Geroscience and pathology: a new frontier in understanding age-related diseases. Pathol Oncol Res. 2024. https:\/\/doi.org\/10.3389\/pore.2024.1611623.","DOI":"10.3389\/pore.2024.1611623"},{"key":"1622_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355. https:\/\/doi.org\/10.1038\/s41568-022-00450-9.","journal-title":"Nat Rev Cancer"},{"key":"1622_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt CA, Wang B, Demaria M. Senescence and cancer - role and therapeutic opportunities. Nat Rev Clin Oncol. 2022;19:619\u201336. https:\/\/doi.org\/10.1038\/s41571-022-00668-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"1622_CR7","doi-asserted-by":"publisher","unstructured":"Evans DS, Young D, Tanaka T, Basisty N, Bandinelli S, Ferrucci L, Campisi J, Schilling B. Proteomic analysis of the senescence-associated secretory phenotype: GDF-15, IGFBP-2, and cystatin-C are associated with multiple aging traits. J Gerontol A Biol Sci Med Sci. 2024;79. https:\/\/doi.org\/10.1093\/gerona\/glad265.","DOI":"10.1093\/gerona\/glad265"},{"key":"1622_CR8","doi-asserted-by":"publisher","first-page":"e3000599","DOI":"10.1371\/journal.pbio.3000599","volume":"18","author":"N Basisty","year":"2020","unstructured":"Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, Holtz A, Shah S, Sharma V, Ferrucci L, Campisi J, Schilling B. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 2020;18:e3000599. https:\/\/doi.org\/10.1371\/journal.pbio.3000599.","journal-title":"PLoS Biol"},{"key":"1622_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2015.11.011","volume":"23","author":"CD Wiley","year":"2016","unstructured":"Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, Shirakawa K, Lim HW, Davis SS, Ramanathan A, Gerencser AA, Verdin E, Campisi J. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 2016;23:303\u201314. https:\/\/doi.org\/10.1016\/j.cmet.2015.11.011. (S1550\u20134131(15)00578\u20131 [pii]).","journal-title":"Cell Metab"},{"key":"1622_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cmet.2016.05.010","volume":"23","author":"CD Wiley","year":"2016","unstructured":"Wiley CD, Campisi J. From ancient pathways to aging cells-connecting metabolism and cellular senescence. Cell Metab. 2016;23:1013\u201321. https:\/\/doi.org\/10.1016\/j.cmet.2016.05.010. (S1550\u20134131(16)30228\u20135 [pii]).","journal-title":"Cell Metab"},{"key":"1622_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685\u2013705. https:\/\/doi.org\/10.1146\/annurev-physiol-030212-183653.","journal-title":"Annu Rev Physiol"},{"key":"1622_CR12","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-024-49106-2","volume":"15","author":"H Bai","year":"2024","unstructured":"Bai H, Liu X, Lin M, Meng Y, Tang R, Guo Y, Li N, Clarke MF, Cai S. Progressive senescence programs induce intrinsic vulnerability to aging-related female breast cancer. Nat Commun. 2024;15:5154. https:\/\/doi.org\/10.1038\/s41467-024-49106-2.","journal-title":"Nat Commun"},{"key":"1622_CR13","doi-asserted-by":"publisher","first-page":"1265911","DOI":"10.3389\/fimmu.2023.1265911","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Huang Y, Li Q, Zhong Y, Zhang Y, Hu J, Liu R, Luo X. Senescence risk score: a multifaceted prognostic tool predicting outcomes, stemness, and immune responses in colorectal cancer. Front Immunol. 2023;14:1265911. https:\/\/doi.org\/10.3389\/fimmu.2023.1265911.","journal-title":"Front Immunol"},{"key":"1622_CR14","doi-asserted-by":"publisher","first-page":"1097513","DOI":"10.3389\/fonc.2023.1097513","volume":"13","author":"J Zhai","year":"2023","unstructured":"Zhai J, Han J, Li C, Lv D, Ma F, Xu B. Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer. Front Oncol. 2023;13:1097513. https:\/\/doi.org\/10.3389\/fonc.2023.1097513.","journal-title":"Front Oncol"},{"key":"1622_CR15","first-page":"569","volume":"13","author":"G Ju","year":"2023","unstructured":"Ju G, Zeng K, Lu L, Diao H, Wang H, Li X, Zhou T. Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data. Am J Cancer Res. 2023;13:569\u201388.","journal-title":"Am J Cancer Res"},{"key":"1622_CR16","doi-asserted-by":"publisher","first-page":"e13853","DOI":"10.1111\/acel.13853","volume":"22","author":"O Garbarino","year":"2023","unstructured":"Garbarino O, Lambroia L, Basso G, Marrella V, Franceschini B, Soldani C, Pasqualini F, Giuliano D, Costa G, Peano C, Barbarossa D, Annarita D, Salvati A, Terracciano L, Torzilli G, Donadon M, Faggioli F. Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis. Aging Cell. 2023;22:e13853. https:\/\/doi.org\/10.1111\/acel.13853.","journal-title":"Aging Cell"},{"key":"1622_CR17","doi-asserted-by":"publisher","first-page":"e13013","DOI":"10.1111\/acel.13013","volume":"18","author":"Y Guo","year":"2019","unstructured":"Guo Y, Ayers JL, Carter KT, Wang T, Maden SK, Edmond D, Newcomb PP, Li C, Ulrich C, Yu M, Grady WM. Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15. Aging Cell. 2019;18:e13013. https:\/\/doi.org\/10.1111\/acel.13013.","journal-title":"Aging Cell"},{"key":"1622_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01384-w","author":"Z Ungvari","year":"2024","unstructured":"Ungvari Z, Ungvari A, Fekete M, Kiss C, Gyorffy B. Senescence-related genes as prognostic indicators in breast cancer survival. Geroscience. 2024. https:\/\/doi.org\/10.1007\/s11357-024-01384-w.","journal-title":"Geroscience"},{"key":"1622_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01164-6","author":"Z Ungvari","year":"2024","unstructured":"Ungvari Z, Ungvari A, Bianchini G, Gyorffy B. Prognostic significance of a signature based on senescence-related genes in colorectal cancer. Geroscience. 2024. https:\/\/doi.org\/10.1007\/s11357-024-01164-6.","journal-title":"Geroscience"},{"key":"1622_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1080\/15384101.2023.2213926","volume":"22","author":"T Zeng","year":"2023","unstructured":"Zeng T, Jiang S, Wang Y, Sun G, Cao J, Hu D, Wang G, Liang X, Ding J, Du J. Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma. Cell Cycle. 2023;22:1434\u201349. https:\/\/doi.org\/10.1080\/15384101.2023.2213926.","journal-title":"Cell Cycle"},{"key":"1622_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4049\/jimmunol.1402643","volume":"195","author":"A Zingoni","year":"2015","unstructured":"Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A. Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells. J Immunol. 2015;195:736\u201348. https:\/\/doi.org\/10.4049\/jimmunol.1402643.","journal-title":"J Immunol"},{"key":"1622_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12885-015-1078-3","volume":"15","author":"R Berenstein","year":"2015","unstructured":"Berenstein R, Blau O, Nogai A, Waechter M, Slonova E, Schmidt-Hieber M, Kunitz A, Pezzutto A, Doerken B, Blau IW. Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer. 2015;15:68. https:\/\/doi.org\/10.1186\/s12885-015-1078-3.","journal-title":"BMC Cancer"},{"key":"1622_CR23","doi-asserted-by":"publisher","first-page":"e59756","DOI":"10.1371\/journal.pone.0059756","volume":"8","author":"T Andre","year":"2013","unstructured":"Andre T, Meuleman N, Stamatopoulos B, De Bruyn C, Pieters K, Bron D, Lagneaux L. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS ONE. 2013;8:e59756. https:\/\/doi.org\/10.1371\/journal.pone.0059756.","journal-title":"PLoS ONE"},{"key":"1622_CR24","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul D, Kosinsky RL, Atkinson EJ, Doolittle ML, Zhang X, LeBrasseur NK, Pignolo RJ, Robbins PD, Niedernhofer LJ, Ikeno Y, Jurk D, Passos JF, Hickson LJ, Xue A, Monroe DG, Tchkonia T, Kirkland JL, Farr JN, Khosla S. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat Commun. 2022;13:4827. https:\/\/doi.org\/10.1038\/s41467-022-32552-1.","journal-title":"Nat Commun"},{"key":"1622_CR25","doi-asserted-by":"publisher","first-page":"e5645","DOI":"10.1371\/journal.pone.0005645","volume":"4","author":"B Gyorffy","year":"2009","unstructured":"Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE. 2009;4:e5645. https:\/\/doi.org\/10.1371\/journal.pone.0005645.","journal-title":"PLoS ONE"},{"key":"1622_CR26","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","volume":"45","author":"B Gyorffy","year":"2023","unstructured":"Gyorffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023;45:1889\u201398. https:\/\/doi.org\/10.1007\/s11357-023-00742-4.","journal-title":"Geroscience"},{"key":"1622_CR27","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gyorffy","year":"2021","unstructured":"Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101\u20139. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.014.","journal-title":"Comput Struct Biotechnol J"},{"key":"1622_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","volume":"181","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024;181:362\u201374. https:\/\/doi.org\/10.1111\/bph.16257.","journal-title":"Br J Pharmacol"},{"key":"1622_CR29","doi-asserted-by":"publisher","first-page":"e82241","DOI":"10.1371\/journal.pone.0082241","volume":"8","author":"B Gyorffy","year":"2013","unstructured":"Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE. 2013;8:e82241. https:\/\/doi.org\/10.1371\/journal.pone.0082241.","journal-title":"PLoS ONE"},{"key":"1622_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"1622_CR31","doi-asserted-by":"publisher","first-page":"e0245824","DOI":"10.1371\/journal.pone.0245824","volume":"16","author":"O Menyhart","year":"2021","unstructured":"Menyhart O, Weltz B, Gy\u0151rffy B. MultipleTesting.com: a tool for life science researchers for multiple hypothesis testing correction. PloS one. 2021;16:e0245824. https:\/\/doi.org\/10.1371\/journal.pone.0245824.","journal-title":"PloS one"},{"key":"1622_CR32","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138. https:\/\/doi.org\/10.1182\/blood-2005-11-013458.","journal-title":"Blood"},{"key":"1622_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2015.309","volume":"30","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, Zangari M, Hoering A, Tian E, Davies FE, Barlogie B, Morgan GJ. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30:423\u201330. https:\/\/doi.org\/10.1038\/leu.2015.309.","journal-title":"Leukemia"},{"key":"1622_CR34","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-022-29824-1","volume":"13","author":"M Troiani","year":"2022","unstructured":"Troiani M, Colucci M, D\u2019Ambrosio M, Guccini I, Pasquini E, Varesi A, Valdata A, Mosole S, Revandkar A, Attanasio G, Rinaldi A, Rinaldi A, Bolis M, Cippa P, Alimonti A. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun. 2022;13:2177. https:\/\/doi.org\/10.1038\/s41467-022-29824-1.","journal-title":"Nat Commun"},{"key":"1622_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.advms.2024.11.001","volume":"70","author":"M Meyer","year":"2024","unstructured":"Meyer M, Fourie C, van der Merwe H, Botha H, Engelbrecht AM. Targeting treatment resistance in cervical cancer: a new avenue for senolytic therapies. Adv Med Sci. 2024;70:33\u201343. https:\/\/doi.org\/10.1016\/j.advms.2024.11.001.","journal-title":"Adv Med Sci"},{"key":"1622_CR36","doi-asserted-by":"publisher","unstructured":"Gaikwad SM, Phyo Z, Arteaga AQ, Gorjifard S, Calabrese DR, Connors D, Huang J, Michalowski AM, Zhang S, Liu ZG, Schneekloth JS, Jr., Mock BA. A small molecule stabilizer of the MYC G4-quadruplex induces endoplasmic reticulum stress, senescence and pyroptosis in multiple myeloma. Cancers (Basel). 2020;12. https:\/\/doi.org\/10.3390\/cancers12102952.","DOI":"10.3390\/cancers12102952"},{"key":"1622_CR37","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.3892\/ol.2018.9474","volume":"16","author":"H Tang","year":"2018","unstructured":"Tang H, Xu L, Liang X, Gao G. Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways. Oncol Lett. 2018;16:6608\u201314. https:\/\/doi.org\/10.3892\/ol.2018.9474.","journal-title":"Oncol Lett"},{"key":"1622_CR38","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","volume":"81","author":"H Fairfield","year":"2021","unstructured":"Fairfield H, Dudakovic A, Khatib CM, Farrell M, Costa S, Falank C, Hinge M, Murphy CS, DeMambro V, Pettitt JA, Lary CW, Driscoll HE, McDonald MM, Kassem M, Rosen C, Andersen TL, van Wijnen AJ, Jafari A, Reagan MR. Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype. Cancer Res. 2021;81:634\u201347. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1088.","journal-title":"Cancer Res"},{"key":"1622_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Johrer K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9:116. https:\/\/doi.org\/10.1186\/s13045-016-0345-3.","journal-title":"J Hematol Oncol"},{"key":"1622_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2141.2009.07670.x","volume":"145","author":"Y Zhou","year":"2009","unstructured":"Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol. 2009;145:637\u201341. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07670.x.","journal-title":"Br J Haematol"},{"key":"1622_CR41","doi-asserted-by":"publisher","first-page":"eabg9551","DOI":"10.1126\/sciadv.abg9551","volume":"7","author":"S Bhalla","year":"2021","unstructured":"Bhalla S, Melnekoff DT, Aleman A, Leshchenko V, Restrepo P, Keats J, Onel K, Sawyer JR, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Dudley JT, Jagannath S, Lagana A, Parekh S. Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Sci Adv. 2021;7:eabg9551. https:\/\/doi.org\/10.1126\/sciadv.abg9551.","journal-title":"Sci Adv"},{"key":"1622_CR42","doi-asserted-by":"publisher","first-page":"100941","DOI":"10.1016\/j.arr.2019.100941","volume":"55","author":"E Sikora","year":"2019","unstructured":"Sikora E, Bielak-Zmijewska A, Mosieniak G. Targeting normal and cancer senescent cells as a strategy of senotherapy. Ageing Res Rev. 2019;55:100941. https:\/\/doi.org\/10.1016\/j.arr.2019.100941.","journal-title":"Ageing Res Rev"},{"key":"1622_CR43","doi-asserted-by":"publisher","unstructured":"Lafontaine J, Cardin GB, Malaquin N, Boisvert JS, Rodier F, Wong P. Senolytic targeting of Bcl-2 anti-apoptotic family increases cell death in irradiated sarcoma cells. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13030386.","DOI":"10.3390\/cancers13030386"},{"key":"1622_CR44","doi-asserted-by":"publisher","first-page":"e13948","DOI":"10.1111\/acel.13948","volume":"22","author":"H Power","year":"2023","unstructured":"Power H, Valtchev P, Dehghani F, Schindeler A. Strategies for senolytic drug discovery. Aging Cell. 2023;22:e13948. https:\/\/doi.org\/10.1111\/acel.13948.","journal-title":"Aging Cell"},{"key":"1622_CR45","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/1878-0261.12761","volume":"14","author":"T Saleh","year":"2020","unstructured":"Saleh T, Carpenter VJ, Tyutyunyk-Massey L, Murray G, Leverson JD, Souers AJ, Alotaibi MR, Faber AC, Reed J, Harada H, Gewirtz DA. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X(L) -BAX interaction. Mol Oncol. 2020;14:2504\u201319. https:\/\/doi.org\/10.1002\/1878-0261.12761.","journal-title":"Mol Oncol"},{"key":"1622_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/acel.12445","volume":"15","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB, Wren JD, Niedernhofer LJ, Robbins PD, Kirkland JL. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15:428\u201335. https:\/\/doi.org\/10.1111\/acel.12445.","journal-title":"Aging Cell"},{"key":"1622_CR47","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, Plesner T, Moreau P, Gibbs SD, Coppola S, Yang X, Al Masud A, Ross JA, Bueno O, Kaufman JL. Phase I Study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39:3602\u201312. https:\/\/doi.org\/10.1200\/JCO.21.00443.","journal-title":"J Clin Oncol"},{"key":"1622_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96:418\u201327. https:\/\/doi.org\/10.1002\/ajh.26083.","journal-title":"Am J Hematol"},{"key":"1622_CR49","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30525-8.","journal-title":"Lancet Oncol"},{"key":"1622_CR50","doi-asserted-by":"publisher","first-page":"1611375","DOI":"10.3389\/pore.2023.1611375","volume":"29","author":"A Cegledi","year":"2023","unstructured":"Cegledi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H, Mikala G. Effective venetoclax-based treatment in relapsed\/refractory multiple myeloma patients with translocation t(6;14). Pathol Oncol Res. 2023;29:1611375. https:\/\/doi.org\/10.3389\/pore.2023.1611375.","journal-title":"Pathol Oncol Res"},{"key":"1622_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bbmt.2005.10.002","volume":"12","author":"JD Shaughnessy Jr","year":"2006","unstructured":"Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:77\u201380. https:\/\/doi.org\/10.1016\/j.bbmt.2005.10.002.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1622_CR52","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","volume":"34","author":"V Sarin","year":"2020","unstructured":"Sarin V, Yu K, Ferguson ID, Gugliemini O, Nix MA, Hann B, Sirota M, Wiita AP. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia. 2020;34:2754\u201365. https:\/\/doi.org\/10.1038\/s41375-020-0785-1.","journal-title":"Leukemia"},{"key":"1622_CR53","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","volume":"22","author":"R Szalat","year":"2016","unstructured":"Szalat R, Avet-Loiseau H, Munshi NC. Gene expression profiles in myeloma: ready for the real world? Clin Cancer Res. 2016;22:5434\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0867.","journal-title":"Clin Cancer Res"},{"key":"1622_CR54","doi-asserted-by":"publisher","unstructured":"Pilcher WC, Yao L, Gonzalez-Kozlova E, Pita-Juarez Y, Karagkouni D, Acharya CR, Michaud ME, Hamilton M, Nanda S, Song Y, Sato K, Wang JT, Satpathy S, Ma Y, Schulman J, D'Souza D, Jayasinghe RG, Cheloni G, Bakhtiari M, Pabustan N, Nie K, Foltz JA, Saldarriaga I, Alaaeldin R, Lepisto E, Chen R, Fiala MA, Thomas BE, Cook A, Dos Santos JV, et al. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.05.15.593193.","DOI":"10.1101\/2024.05.15.593193"},{"key":"1622_CR55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41416-021-01371-4","volume":"125","author":"A Jafari","year":"2021","unstructured":"Jafari A, Fairfield H, Andersen TL, Reagan MR. Myeloma-bone marrow adipocyte axis in tumour survival and treatment response. Br J Cancer. 2021;125:775\u20137. https:\/\/doi.org\/10.1038\/s41416-021-01371-4.","journal-title":"Br J Cancer"},{"key":"1622_CR56","doi-asserted-by":"publisher","first-page":"584683","DOI":"10.3389\/fonc.2020.584683","volume":"10","author":"H Fairfield","year":"2020","unstructured":"Fairfield H, Costa S, Falank C, Farrell M, Murphy CS, D\u2019Amico A, Driscoll H, Reagan MR. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2020;10:584683. https:\/\/doi.org\/10.3389\/fonc.2020.584683.","journal-title":"Front Oncol"},{"key":"1622_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-17-0604","volume":"6","author":"C Borrelli","year":"2018","unstructured":"Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A. Drug-induced senescent multiple myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL15 trans-presentation. Cancer Immunol Res. 2018;6:860\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0604.","journal-title":"Cancer Immunol Res"},{"key":"1622_CR58","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bone.2003.07.005","volume":"33","author":"K Stenderup","year":"2003","unstructured":"Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33:919\u201326. https:\/\/doi.org\/10.1016\/j.bone.2003.07.005.","journal-title":"Bone"},{"key":"1622_CR59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/bloodadvances.2022007033","volume":"7","author":"C Hellmich","year":"2023","unstructured":"Hellmich C, Wojtowicz E, Moore JA, Mistry JJ, Jibril A, Johnson BB, Smith JGW, Beraza N, Bowles KM, Rushworth SA. p16INK4A-dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors. Blood Adv. 2023;7:256\u201368. https:\/\/doi.org\/10.1182\/bloodadvances.2022007033.","journal-title":"Blood Adv"},{"key":"1622_CR60","doi-asserted-by":"publisher","unstructured":"Ruiz-Aparicio PF, Vernot JP. Bone marrow aging and the leukaemia-induced senescence of mesenchymal stem\/stromal cells: exploring similarities. J Pers Med. 2022;12. https:\/\/doi.org\/10.3390\/jpm12050716.","DOI":"10.3390\/jpm12050716"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01622-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01622-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01622-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T14:01:59Z","timestamp":1750514519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01622-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01622-9","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Balazs Gyorffy serves as Associate Editor for GeroScience. Dr. Zoltan Ungvari serves as Editor-in-Chief for GeroScience.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}